Pilar Castillo Grau

Prospective validation of the EASL-EASD algorithm for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes

Clara Amiama Roig, Miriam Romero, Noemí González, Pilar Castillo Grau et autres

BACKGROUND AND AIM: individuals with type 2 diabetes are at increased risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD). The European Association for the Study of Diabetes (EASD) recently proposed a two-step algorithm for risk stratification and referral, developed in collaboration …

es (code pays fourni par la source)

Fontan-associated liver disease after heart transplant

Inés Ponz de Antonio, Pilar Castillo Grau, Ángel Aroca Peinado

es (code pays fourni par la source)

Low phospholipid-associated cholelithiasis syndrome (LPAC), a not uncommon cause of biliary problems and hospital admissions.

Isabel María Spigarelli, Beatriz Pillado, David Vincent, Joaquín Poza Cordón et autres

BACKGROUND AND AIMS: biliary diseases are a major cause of morbidity and mortality for patients and a burden for the healthcare system. The genetic syndrome of low phospholipid-associated cholelithiasis (LPAC) is a little known and rare entity whose treatment with bile salts …

es, co (code pays fourni par la source)

Evolución postrasplante de la hepatopatía asociada a Fontan

Inés Ponz de Antonio, Pilar Castillo Grau, Ángel Aroca Peinado

es (code pays fourni par la source)

Patients with hepatitis C lost to follow-up: ethical-legal aspects and search results

Irene Andaluz García, María del Mar Arcos-Rueda, María Dolores Montero Vega, Pilar Castillo Grau et autres

INTRODUCTION: data on the prevalence and characteristics of hepatitis C patients lost to follow-up are lacking. In addition, the identification of this population clashes with data protection regulations. METHODS: the identification and contact protocol was submitted to the Health Care Ethics Committee. …

es (code pays fourni par la source)

Syndrome of inappropriate antidiuretic hormone secretion following transarterial chemoembolisation of hepatocellular carcinoma

Jorge Yebra Carmona, Marta Jaquotot Herranz, Mariana Tavecchia, Pilar Castillo Grau

es (code pays fourni par la source)

Quality of life study in asymptomatic patients with hepatitis C

Raúl Honrubia López, Antonio Madejón Seiz, Miriam Romero Portales, Araceli García Sánchez et autres

OBJECTIVE AND METHODS: an observational, longitudinal, prospective study was performed to assess changes in perceived quality of life in asymptomatic patients with hepatitis C under treatment with direct-acting antivirals. Questionnaires SF-36 and EQ-5D-5L were administered to 86 treated patients and 12 controls. …

es (code pays fourni par la source)

Síndrome de secreción inadecuada de hormona antidiurética postquimioembolización transarterial de un carcinoma hepatocelular

Jorge Yebra Carmona, Marta Jaquotot Herranz, Mariana Tavecchia, Pilar Castillo Grau

es (code pays fourni par la source)

Practical aspects of high resolution esophageal manometry

Antonio Ruiz de León San Juan, Constanza Ciriza de los Ríos, Julio Pérez de la Serna y Bueno, Fernando Canga Rodríguez‐Valcárcel et autres

High resolution esophageal manometry (HRM) is currently under development as can be seen in the various Chicago classifications. In order to standardize criteria in certain practical aspects with limited scientific evidence, the First National Meeting for Consensus in High Resolution Manometry of …

es (code pays fourni par la source)

Creación de ascitis artificial para el tratamiento mediante radiofrecuencia percutánea del hepatocarcinoma cercano al diafragma

Luisa Adán Merino, Juan Pedro Pérez Robledo, I. Prieto, Francisco Gea Rodríguez et autres

es (code pays fourni par la source)

Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage

Luisa Adán Merino, C. Prados, Francisco Gea Rodríguez, Pilar Castillo Grau et autres

The standard treatment of chronic hepatitis C, pegylated interferon and ribavirin (pegI/R), has many limitations in both effectiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients. In hepatitis C virus-infected cystic fibrosis patients this treatment could increase …

es (code pays fourni par la source)

Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage Tratamiento de hepatitis crónica C en un paciente con fibrosis quística en situación de pretrasplante pulmonar

Luisa Adán Merino, C. Prados, Francisco Gea Rodríguez, Pilar Castillo Grau et autres

The standard treatment of chronic hepatitis C, pegylated interferon and ribavirin (pegI/R), has many limitations in both effectiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients. In hepatitis C virus-infected cystic fibrosis patients this treatment could increase …